Understanding Melanoma in the Leptomeninges
At a Glance
Leptomeningeal melanoma happens when melanoma cells spread into the fluid and membranes around the brain and spinal cord. It is serious, but prognosis and treatment vary widely; care is individualized based on symptoms, overall health, disease elsewhere, tumor mutations, and treatment response.
Facing a diagnosis of leptomeningeal disease (LMD), also known as leptomeningeal metastasis from melanoma, is an overwhelming and frightening experience. It is a serious complication of advanced melanoma, and it is entirely natural to feel a high degree of anxiety. Understanding what is happening in your body and how the medical community approaches this condition is the first step in preparing for the conversations ahead with your care team.
Understanding the Anatomy
To understand LMD, it helps to visualize the protective layers around your brain and spinal cord.
- The Leptomeninges: Your central nervous system is wrapped in three protective layers. The inner two layers—the pia mater and the arachnoid mater—are collectively called the leptomeninges [1].
- Cerebrospinal Fluid (CSF): Between these two layers is a space filled with cerebrospinal fluid (CSF), a clear liquid that cushions the brain and spinal cord and provides them with nutrients [1].
LMD occurs when melanoma cells enter this fluid-filled space. Because the CSF circulates, cancer cells can travel through the fluid and settle across different areas of the central nervous system [1].
How Melanoma Enters the CSF
Melanoma cells can reach the leptomeningeal space through several routes:
- Bloodstream Travel: Cancer cells can travel through the blood and cross the specialized blood-CSF barrier [1].
- Direct Extension: If a melanoma tumor is already growing in the brain or spine, it may grow through the tissue and enter the surrounding fluid [2].
- Surgical Transfer: In some cases, if a brain tumor near a fluid-filled cavity (ventricle) is surgically removed, cells may inadvertently enter the fluid during the procedure [3].
LMD is a serious stage of the disease, and studies suggest that approximately 10% to 15% of patients with advanced melanoma or melanoma with CNS involvement will develop LMD at some point [4][5].
A Unique Environment for Cancer
The CSF is more than just a liquid cushion; it is a distinct biological environment that makes treating LMD particularly challenging.
- An Immunosuppressive Space: The CSF is an immunologically distinct compartment. While it does contain immune cells, the tumor environment in LMD can be highly immunosuppressive, limiting the activity of the immune cells (like T-cells) that usually fight cancer [6]. This can allow melanoma cells to grow with less interference [7].
- Survival Signals: The surrounding leptomeningeal tissues and fluid can interact with the cancer, providing chemical signals that may help the melanoma cells survive and resist certain treatments [8][9].
- The Protective Barriers: The blood-brain barrier and blood-CSF barrier, which protect your brain from toxins, also block many standard systemic drugs from reaching the cancer cells in the CSF [10].
Prognosis and Survival Statistics
Historically, the prognosis for melanoma LMD was very poor, with older cohorts showing median survival times of only 3 to 4 months [11][12].
It is crucial to understand that a median survival statistic is a group average from a specific study era, not a prediction for your individual outcome. Modern treatment eras have seen group medians improve to approximately 7 to 10 months in selected cohorts, with some patients achieving longer, durable control [13][14].
Survival depends heavily on your performance status (your ability to perform daily tasks), how well the cancer is controlled in the rest of your body, your specific genetic mutations, and your response to newer targeted therapies and immunotherapies [12][15].
Goals of Care
Because every case of LMD is different, your doctors will emphasize individualized care. The goals are typically focused on:
- Disease-Directed Treatment: Using the most effective therapies (systemic or local) tailored to your specific tumor type and mutation status [16].
- Palliative and Supportive Care: Managing symptoms to ensure you can continue to engage with your daily activities and remain as comfortable as possible. Palliative care is provided alongside active cancer treatment, not instead of it [17].
- Neurological Protection: Delaying or preventing the worsening of neurological symptoms [17].
While the path forward is difficult, your care team will work across multiple specialties—including neuro-oncology, radiation oncology, and supportive care—to create a plan tailored to your specific situation, goals, and values [18].
Common questions in this guide
What is leptomeningeal melanoma or melanoma-related LMD?
How is melanoma-related leptomeningeal disease confirmed?
What is the prognosis for leptomeningeal melanoma?
How is leptomeningeal disease from melanoma treated?
Can a BRAF mutation change my treatment options?
Which symptoms should I report to my care team?
Which specialists may help care for melanoma-related LMD?
Get notified when new evidence is published on leptomeningeal melanoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (18)
- 1
[Spinal metastases combined with leptomeningeal metastasis: A case report].
Ma LJ, Hu PP, Liu XG
Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 2023; (55(3)):563-566.
PMID: 37291936 - 2
Surgical and anatomic factors predict development of leptomeningeal disease in patients with melanoma brain metastases.
Lowe SR, Wang CP, Brisco A, et al.
Neuro-oncology 2022; (24(8)):1307-1317 doi:10.1093/neuonc/noac023.
PMID: 35092434 - 3
The anatomic basis of leptomeningeal metastasis.
Freret ME, Boire A
The Journal of experimental medicine 2024; (221(4)) doi:10.1084/jem.20212121.
PMID: 38451255 - 4
Leptomeningeal Metastases in Melanoma Patients: An Update on and Future Perspectives for Diagnosis and Treatment.
Steininger J, Gellrich FF, Engellandt K, et al.
International journal of molecular sciences 2023; (24(14)) doi:10.3390/ijms241411443.
PMID: 37511202 - 5
Outcomes and prognostic factors in melanoma patients with leptomeningeal disease: a retrospective cohort study.
Aboelatta MA, Rezazadeh A, Sener U, et al.
Melanoma research 2026; (36(3)):203-210 doi:10.1097/CMR.0000000000001088.
PMID: 42053986 - 6
Leptomeningeal Disease (LMD) in Patients with Melanoma Metastases.
Khaled ML, Tarhini AA, Forsyth PA, et al.
Cancers 2023; (15(6)) doi:10.3390/cancers15061884.
PMID: 36980770 - 7
CD11c+CD163+ Cells and Signal Transducer and Activator of Transcription 3 (STAT3) Expression Are Common in Melanoma Leptomeningeal Disease.
Najem H, Marisetty A, Horbinski C, et al.
Frontiers in immunology 2021; (12()):745893 doi:10.3389/fimmu.2021.745893.
PMID: 34691054 - 8
Spatial transcriptomics analysis identifies a unique tumor-promoting function of the meningeal stroma in melanoma leptomeningeal disease.
Alhaddad H, Ospina OE, Khaled ML, et al.
bioRxiv : the preprint server for biology 2023; doi:10.1101/2023.12.18.572266.
PMID: 38187574 - 9
Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease.
Law V, Smalley I, Evernden BR, et al.
Journal of visualized experiments : JoVE 2024; doi:10.3791/66071.
PMID: 38619274 - 10
Complement Component 3 Adapts the Cerebrospinal Fluid for Leptomeningeal Metastasis.
Boire A, Zou Y, Shieh J, et al.
Cell 2017; (168(6)):1101-1113.e13 doi:10.1016/j.cell.2017.02.025.
PMID: 28283064 - 11
Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities.
Chorti E, Kebir S, Ahmed MS, et al.
European journal of cancer (Oxford, England : 1990) 2021; (148()):395-404 doi:10.1016/j.ejca.2021.02.016.
PMID: 33789203 - 12
Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).
Ferguson SD, Bindal S, Bassett RL, et al.
Journal of neuro-oncology 2019; (142(3)):499-509 doi:10.1007/s11060-019-03121-2.
PMID: 30847840 - 13
Melanoma leptomeningeal disease: Advances in diagnosis and emerging therapeutic strategies.
Middleton ML, Lucke-Wold B
World journal of experimental medicine 2026; (16(1)):117938 doi:10.5493/wjem.v16.i1.117938.
PMID: 41883443 - 14
Survival improvements in patients with melanoma brain metastases and leptomeningeal disease in the modern era: Insights from a nationwide study (2015-2022).
Pedersen S, Johansen EL, Højholt KL, et al.
European journal of cancer (Oxford, England : 1990) 2025; (217()):115253 doi:10.1016/j.ejca.2025.115253.
PMID: 39874911 - 15
Survival and treatment outcomes in patients with leptomeningeal disease from metastatic melanoma.
Saberian C, Milton DR, Simon J, et al.
Neuro-oncology practice 2024; (11(4)):452-463 doi:10.1093/nop/npae026.
PMID: 39006528 - 16
Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions.
Wilcox JA, Chukwueke UN, Ahn MJ, et al.
Neuro-oncology 2024; (26(10)):1781-1804 doi:10.1093/neuonc/noae103.
PMID: 38902944 - 17
How we treat patients with leptomeningeal metastases.
Le Rhun E, Preusser M, van den Bent M, et al.
ESMO open 2019; (4(Suppl 2)):e000507 doi:10.1136/esmoopen-2019-000507.
PMID: 31231573 - 18
Decision-Making in Intrathecal Therapy for Leptomeningeal Disease.
Weindler S, Hundsberger T, Addeo A, et al.
Oncology 2026; (104(10)):1203-1214 doi:10.1159/000552332.
PMID: 42166400
This page is for informational purposes only and does not constitute medical advice. Your neuro-oncology team can interpret your MRI, CSF results, symptoms, and treatment options for your specific situation.